|
목적 : To evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (VEGF) agents for treatment of neovascular age-related macular degeneration (nAMD) in vitrectomized eye
방법 : A retrospective chart review was conducted to identify patients treated for nAMD using anti-VEGF agents after pars plana vitrectomy (PPV). PPV was performed with complete PVD induction without lensectomy. Patients who had choroidal neovascularization or macular edema due to other causes were excluded. Demographic data, visual acuity, central foveal thickness on optical coherence tomography at 1 month after first injection and serial injection were reviewed.
결과 : 44 eyes from 44 patients were included. Mean central foveal thickness was 478.50±156.93 μm at baseline, 414.25±143.55 μm at 1 month after first injection (P-value<0.001) and 386.75±141.45 μm at 1 month after serial injection (P-value<0.001). Mean LogMAR visual acuity (VA) was 0.91±0.61 at baseline, 0.89±0.66 at 1 month after first injection and 0.89±0.67 at 1 month after serial injection. VA improved in 34.1% at 1 month after first injection and 43.2% at 1 month after serial injection.
결론 : Intravitreal anti-VEGF agents showed favorable anatomical improvement in neovascular age-related macular degeneration after pars plana vitrectomy without lensectomy.
|